Alnylam Pharmaceuticals (ALNY) Tax Provisions (2009 - 2026)

Alnylam Pharmaceuticals has reported Tax Provisions for 12 years, with the latest figure at $15.7 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions fell 1.39% year-over-year to $15.7 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (up 110.72% YoY), and the FY2025 full-year result was $9.4 million, up 109.48% from the prior year.
• Tax Provisions for Q1 2026 stood at $15.7 million, up from -$25.3 million in the prior quarter.
• The five-year high for Tax Provisions was $30.9 million in Q2 2025, with the low at -$110.2 million in Q4 2024.
• Historically, Tax Provisions has averaged -$3.7 million across 5 years, with a median of $1.8 million in 2023.
• Annual changes were most pronounced in 2023 — Tax Provisions soared 13091.3% — and 2024, when it tumbled 60315.85%.
• Alnylam Pharmaceuticals' Tax Provisions stood at $472000.0 in 2022, then slumped by 61.23% to $183000.0 in 2023, then plunged by 60315.85% to -$110.2 million in 2024, then jumped by 77.06% to -$25.3 million in 2025, then soared by 161.95% to $15.7 million in 2026.
• The last three Tax Provisions figures came in at $15.7 million (Q1 2026), -$25.3 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.